Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Torrent Pharmaceuticals stock price, quote, forecast and news

TORNTPHARM.NS
INE685A01028

Price

3,457.80
Today +/-
+1.14
Today %
+3.11 %
P

Torrent Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Torrent Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Torrent Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Torrent Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Torrent Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Torrent Pharmaceuticals Stock Price History

DateTorrent Pharmaceuticals Price
9/20/20243,457.80 undefined
9/19/20243,351.90 undefined
9/18/20243,359.60 undefined
9/17/20243,453.25 undefined
9/16/20243,453.90 undefined
9/13/20243,451.70 undefined
9/12/20243,452.00 undefined
9/11/20243,435.55 undefined
9/10/20243,426.15 undefined
9/9/20243,438.75 undefined
9/6/20243,416.70 undefined
9/5/20243,430.95 undefined
9/4/20243,462.85 undefined
9/3/20243,443.80 undefined
9/2/20243,442.00 undefined
8/30/20243,485.15 undefined
8/29/20243,434.55 undefined
8/28/20243,435.05 undefined
8/27/20243,362.00 undefined
8/26/20243,342.80 undefined

Torrent Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Torrent Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Torrent Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Torrent Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Torrent Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Torrent Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Torrent Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Torrent Pharmaceuticals’s growth potential.

Torrent Pharmaceuticals Revenue, EBIT and net profit per share

DateTorrent Pharmaceuticals RevenueTorrent Pharmaceuticals EBITTorrent Pharmaceuticals Net Income
2027e154.16 B undefined43.15 B undefined31.79 B undefined
2026e138.39 B undefined37.61 B undefined26.91 B undefined
2025e122.51 B undefined31.38 B undefined20.7 B undefined
2024107.28 B undefined25.72 B undefined16.56 B undefined
202396.2 B undefined21.4 B undefined12.45 B undefined
202285.08 B undefined17.69 B undefined7.77 B undefined
202180.05 B undefined18.28 B undefined12.52 B undefined
202079.39 B undefined15.19 B undefined10.25 B undefined
201976.73 B undefined13.69 B undefined4.36 B undefined
201859.5 B undefined9.41 B undefined6.78 B undefined
201758.57 B undefined10.84 B undefined9.34 B undefined
201666.87 B undefined24.96 B undefined17.33 B undefined
201546.54 B undefined8.3 B undefined7.51 B undefined
201441.85 B undefined9.53 B undefined6.64 B undefined
201332.11 B undefined6.15 B undefined4.33 B undefined
201226.96 B undefined4.41 B undefined2.84 B undefined
201121.98 B undefined3.26 B undefined2.7 B undefined
201019.04 B undefined3.44 B undefined2.31 B undefined
200916.31 B undefined2.61 B undefined1.84 B undefined
200813.55 B undefined1.64 B undefined1.35 B undefined
200712.88 B undefined1.12 B undefined935 M undefined
20069.54 B undefined690 M undefined509 M undefined
20055.46 B undefined534 M undefined488 M undefined

Torrent Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
3.352.893.923.643.973.794.555.469.5412.8813.5516.3119.0421.9826.9632.1141.8546.5466.8758.5759.576.7379.3980.0585.0896.2107.28122.51138.39154.16
--13.6635.87-7.299.15-4.5620.1119.9074.7235.065.1920.3616.7615.4322.6619.1130.3211.2043.70-12.411.5928.963.470.836.2913.0711.5114.2012.9611.40
46.4350.7653.0861.0560.5961.5863.2567.4464.1165.1865.0163.4969.2366.7966.6669.8668.9268.3173.8967.0570.1469.7471.6372.0870.1870.6174.01---
1.551.472.082.222.412.332.883.686.118.398.8110.3513.1814.6817.9722.4328.8431.7949.4139.2741.7353.5156.8757.759.7167.9279.4000
0.470.350.790.60.630.530.720.530.691.121.642.613.443.264.416.159.538.324.9610.849.4113.6915.1918.2817.6921.425.7231.3837.6143.15
14.0512.1920.1116.3815.9414.0415.759.787.248.7012.1116.0018.0414.8416.3719.1422.7717.8337.3218.5115.8117.8419.1322.8420.8022.2523.9825.6227.1727.99
0.390.330.430.390.50.440.550.490.510.941.351.842.312.72.844.336.647.5117.339.346.784.3610.2512.527.7712.4516.5620.726.9131.79
--14.0328.70-7.9827.30-11.2223.02-10.464.3083.6944.0636.9025.3816.875.1152.3953.4013.10130.82-46.13-27.37-35.66134.8622.17-37.9260.2233.0124.9729.9818.14
------------------------------
------------------------------
339339339339339339339339338338338338338338338338338338338338338338338338338338.45338.45000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Torrent Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Torrent Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
0.040.080.280.090.50.350.140.110.850.211.182.33.886.047.66.869.548.6314.2416.9713.611.646.627.385.837.2310.04
1.170.30.320.380.380.260.420.631.732.282.110.310.310.110.196.8810.9915.9514.459.5112.5414.3616.4915.2316.3319.4618.45
2.183.161.030.570.360.260.270.380.390.530.233.64.094.465.972.022.712.593.183.034.373.493.463.722.892.913.5
0.610.430.60.780.820.80.971.482.252.582.313.223.35.055.329.2410.0611.1314.2716.3320.5220.1922.1227.3425.1922.8123.24
000000.050.040.060.140.170.770.10.030.290.80.610.742.690.742.951.610.71.111.552.710.880.89
4.013.972.231.822.051.731.842.655.365.776.69.5311.6115.9419.8725.6134.0540.9946.8848.7952.6250.3849.8155.2352.9553.2956.11
1.471.571.591.741.761.852.12.943.884.475.055.36.167.958.9210.8313.8115.6120.1723.3428.432.835.336.2932.4734.635.78
0.460.460.460.460.070.150.221.47000.551.41.410.20.38000.010000.650.940.680.680.710.33
00000000000000.60.610.591.030.3411.821.491.642.390.971.671.613.35
00000000.040.170.220.20.2300.20.240.230.2917.8617.5917.1452.6347.543.7339.8435.4650.945.83
000000.010.0100.01000000001.251.251.63.993.353.423.412.63.383.38
0.240.260.230.18000000.120.340.220.480.60.580.591.533.593.694.323.34.94.524.335.185.645.82
2.172.292.282.381.8322.334.464.064.816.147.148.059.5510.7312.2316.6538.6643.748.2389.8190.8490.2985.5178.0596.8394.49
6.186.264.514.23.893.734.167.119.4210.5812.7416.6819.6525.530.637.8450.779.6490.5897.02142.43141.21140.1140.75131150.12150.61
                                                     
0.460.460.460.210.210.210.210.210.420.420.420.420.420.420.420.420.850.850.850.850.850.850.850.850.851.691.69
42842842842842842842842842842842843142842842842843434343434343434300
1.181.371.561.771.661.872.222.522.633.254.255.77.429.3411.3613.4118.0324.8534.2341.4545.5946.2248.9958.1259.2262.2968.68
0000000000-0.01-0.050.040.04-0.27-0.040.110.69-0.181.16-0.260.13-1.64-0.64-0.58-2-1.81
000000000000000000000000000
2.072.262.442.412.292.512.863.163.484.15.16.518.3110.2211.9414.2219.0226.4334.9443.546.2247.2448.2358.3759.5361.9868.56
1.040.390.660.70.730.570.691.162.332.492.263.133.846.158.6410.6814.2918.2822.617.4920.4820.9720.4920.6716.7416.7920.89
0.040.040.010.0100000.0100.010.020.020.020.020.540.671.441.971.662.222.271.971.931.82.62.24
0.340.40.570.220.250.270.260.290.470.31.081.51.642.182.413.52.911.773.275.545.817.176.727.216.526.897.58
000000000000011.381.252.13.190.03016.269.3410.917.049.2317.6516.38
000.050.070000000001.791.191.141.772.364.982.697.2511.9114.4512.079.8710.547.16
1.410.831.2910.990.840.951.452.812.83.354.665.511.1413.6317.1121.7527.0532.8527.3852.0251.6554.5448.9244.1554.4754.25
2.73.180.770.790.220.0402.122.652.993.64.835.222.933.224.557.4521.7318.522.4141.1239.1333.0429.6321.625.4916.68
00000.390.340.360.380.480.70.70.680.620.620.630.570.482.281.721.0100.08001.944.026.56
00000000000000.571.141.42.012.152.562.713.073.114.293.833.784.154.55
2.73.180.770.790.610.380.362.53.133.684.295.515.854.1156.519.9326.1622.7826.1344.1842.3137.3233.4627.3233.6627.79
4.114.012.061.791.591.221.33.955.946.487.6510.1711.3415.2518.6323.6231.6753.2155.6353.5196.2193.9791.8782.3871.4788.1482.04
6.186.264.514.23.893.734.177.119.4210.5812.7416.6719.6525.4830.5637.8450.779.6490.5797.02142.43141.21140.1140.75131150.12150.61
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Torrent Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Torrent Pharmaceuticals's financial health and stability.

Assets

Torrent Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Torrent Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Torrent Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Torrent Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.420.410.560.570.650.610.80.570.781.091.491.923.473.423.595.828.449.423.4310.889.315.6211.8715.2612.2618.47
0.070.070.090.110.140.150.160.190.260.330.390.420.660.630.820.830.871.912.383.074.096.186.546.586.627.07
00000000000000000000000000
-459386-154-470-177-228-455-524-744-911220-163-1,409-221609-5,543-3,814-4,676-1,458-5,095-6,385-1,818-6,699-5,138-7,729-3,574
0.160.080.150.120.05-0.020.020.020.060.210.280.40.150.12-0.020.430.51.473.151.231.988.012.223.356.882.31
0.150.110.370.110.10.010.010.060.180.250.210.270.260.290.310.310.611.952.121.912.765.034.853.562.583.03
0.050.070.050.170.130.230.230.070.110.20.250.260.660.840.831.332.620.585.773.842.842.812.841.764.213.98
0.190.940.650.320.670.520.520.250.340.722.372.582.873.954.991.545.998.127.510.098.9917.9813.9320.0518.0324.27
-234-132-111-269-203-229-450-974-1,340-999-1,284-627-1,501-2,650-1,613-2,929-4,001-2,426-5,991-4,868-7,913-6,628-4,068-3,352-2,026-5,739
-0.92-1.112.08-0.070.33-0.19-0.3-0.9-1.28-0.91-1.35-0.4-1.29-2.33-1.37-2.42-3.56-21.62-8.38-7.87-47.07-2.411.99-4.49-1.97-24.15
-0.68-0.982.190.20.540.040.150.070.060.09-0.060.230.210.320.240.510.44-19.2-2.39-3-39.164.226.05-1.140.06-18.41
00000000000000000000000000
0.470.48-2.350.04-0.63-0.18-0.042.120.530.350.530.420.610.19-0.251.394.1416.06-3.842.0239.58-5.01-3.45-9.56-8.4612.43
25000-2500000000000000000000000
0.710.21-2.54-0.45-0.81-0.37-0.241.870.22-0.430.31-0.18-0.05-0.68-1.930.20.8612.12-14.35-1.9334.17-13.15-15.49-16.51-17.810.77
120-120000-17-8-61-122-249-213-268-254-270-304-361-603-1,942-2,117-1,913-2,757-5,034-4,854-3,561-2,577-3,030
-128-147-183-235-174-168-191-191-193-532-1-332-410-591-1,373-834-2,674-1,997-8,397-2,037-2,648-3,097-7,185-3,385-6,769-8,630
-0.020.040.2-0.20.19-0.04-0.021.22-0.72-0.641.331.971.60.941.56-0.732.68-0.94.370.18-3.662.380.73-0.89-1.741.1
-448085375446229068-722-996-2811,0901,9521,3691,3003,378-1,3941,9935,67621,5105,2201,08111,3539,86116,70216,00418,530.2
00000000000000000000000000

Torrent Pharmaceuticals stock margins

The Torrent Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Torrent Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Torrent Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Torrent Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Torrent Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Torrent Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Torrent Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Torrent Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Torrent Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Torrent Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Torrent Pharmaceuticals Margin History

Torrent Pharmaceuticals Gross marginTorrent Pharmaceuticals Profit marginTorrent Pharmaceuticals EBIT marginTorrent Pharmaceuticals Profit margin
2027e74.01 %27.99 %20.62 %
2026e74.01 %27.17 %19.44 %
2025e74.01 %25.62 %16.9 %
202474.01 %23.98 %15.44 %
202370.61 %22.25 %12.94 %
202270.18 %20.8 %9.13 %
202172.08 %22.84 %15.64 %
202071.63 %19.13 %12.91 %
201969.74 %17.84 %5.69 %
201870.14 %15.81 %11.4 %
201767.05 %18.51 %15.94 %
201673.89 %37.32 %25.92 %
201568.31 %17.83 %16.14 %
201468.92 %22.77 %15.86 %
201369.86 %19.14 %13.48 %
201266.66 %16.37 %10.53 %
201166.79 %14.84 %12.29 %
201069.23 %18.04 %12.14 %
200963.49 %16 %11.31 %
200865.01 %12.11 %9.94 %
200765.18 %8.7 %7.26 %
200664.11 %7.24 %5.34 %
200567.44 %9.78 %8.94 %

Torrent Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Torrent Pharmaceuticals earnings per share therefore indicates how much revenue Torrent Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Torrent Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Torrent Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Torrent Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Torrent Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Torrent Pharmaceuticals Revenue, EBIT and net profit per share

DateTorrent Pharmaceuticals Sales per ShareTorrent Pharmaceuticals EBIT per shareTorrent Pharmaceuticals Earnings per Share
2027e455.49 undefined0 undefined93.92 undefined
2026e408.89 undefined0 undefined79.5 undefined
2025e361.98 undefined0 undefined61.16 undefined
2024316.97 undefined76 undefined48.94 undefined
2023284.25 undefined63.23 undefined36.79 undefined
2022251.72 undefined52.35 undefined22.99 undefined
2021236.83 undefined54.09 undefined37.04 undefined
2020234.89 undefined44.94 undefined30.32 undefined
2019227.01 undefined40.49 undefined12.91 undefined
2018176.03 undefined27.83 undefined20.06 undefined
2017173.28 undefined32.07 undefined27.62 undefined
2016197.84 undefined73.83 undefined51.28 undefined
2015137.68 undefined24.54 undefined22.22 undefined
2014123.81 undefined28.19 undefined19.64 undefined
201395 undefined18.18 undefined12.8 undefined
201279.76 undefined13.06 undefined8.4 undefined
201165.02 undefined9.65 undefined7.99 undefined
201056.33 undefined10.16 undefined6.84 undefined
200948.25 undefined7.72 undefined5.46 undefined
200840.08 undefined4.85 undefined3.99 undefined
200738.1 undefined3.31 undefined2.77 undefined
200628.21 undefined2.04 undefined1.51 undefined
200516.1 undefined1.58 undefined1.44 undefined

Torrent Pharmaceuticals business model

Torrent Pharmaceuticals Ltd is a company from India that was founded in 1959. Initially, it exclusively produced generics, which are imitation drugs of existing medications, but over the years it expanded its portfolio. Today, Torrent Pharmaceuticals Ltd is a significant player in the international pharmaceutical market and offers a variety of products. The business model of Torrent Pharmaceuticals Ltd is based on a smart strategy: the company not only focuses on generics but also develops its own active ingredients and patents. Another strength of Torrent Pharmaceuticals Ltd lies in its marketing. It has a strong network of distribution partners in various countries, allowing it to quickly and efficiently respond to local needs. The company is divided into three areas: generics, branded drugs, and API (Active Pharmaceutical Ingredients). In the generics area, Torrent Pharmaceuticals Ltd offers a wide range of medications, from antibiotics to painkillers. It focuses on both the Indian market and international exports. In the branded drugs area, the company develops its own active ingredients and patents and markets them worldwide. It focuses on innovative preparations, such as medications for cancer or diabetes. A well-known product in this area is the cholesterol-lowering drug Rosuvastatin, marketed under the brand name Rosuvas®. In the API area, Torrent Pharmaceuticals Ltd manufactures active ingredients that serve as raw materials for medications. This includes both generics and branded drugs. With this division, the company covers the entire value chain and thus has a high level of control over the quality of its products. Torrent Pharmaceuticals Ltd operates multiple production facilities in India. Here, the various medications are manufactured and quality tested. The company places great importance on adhering to international standards and therefore has a number of certifications. For example, it is certified according to ISO 9001 and ISO 14001 and has British MHRA approval as well as American FDA approval. In recent years, Torrent Pharmaceuticals Ltd has increasingly focused on the international market. It now exports to over 60 countries, including the USA, Europe, and Australia. The company aims to continuously expand its product range and invests in research and development. The company places special emphasis on the quality of its products. It follows a holistic quality approach that extends from development to production to delivery. The company has its own quality control laboratories and collaborates closely with independent testing institutes. This ensures a high quality of its medications and a high level of safety for its customers. In summary, Torrent Pharmaceuticals Ltd is a significant player in the international pharmaceutical market. With its wide range of generics, branded drugs, and API, it adopts a diversified strategy and is well positioned for the future. The company places great importance on the quality of its products and therefore invests in research and development, as well as adherence to international standards. With its focus on international exports and innovative preparations, it is an attractive partner for customers worldwide. Torrent Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Torrent Pharmaceuticals SWOT Analysis

Strengths

Torrent Pharmaceuticals Ltd is an established and reliable pharmaceutical company with a long-standing presence in the market. With years of experience and a strong track record, the company has built a solid reputation for delivering high-quality products and services.

Torrent Pharmaceuticals Ltd offers a wide range of pharmaceutical products across various therapeutic categories. This diversified product portfolio helps the company to cater to diverse customer needs and reduces the dependency on a single product or market segment.

The company has a well-established research and development (R&D) division, which enables it to continuously innovate and develop new drugs. This strengthens its competitive edge and allows Torrent Pharmaceuticals Ltd to stay ahead in the market by introducing novel and effective treatments.

Weaknesses

Torrent Pharmaceuticals Ltd relies heavily on patents for its revenue generation. The expiration of patents can lead to generic competition and potentially impact the company's financial performance. This vulnerability to patent expiry is a weakness that needs to be managed effectively.

Although the company has a strong domestic presence, its global footprint is relatively limited. This lack of international reach may restrict opportunities for growth and expansion in emerging markets. Torrent Pharmaceuticals Ltd needs to explore strategies to enter new markets and increase its global presence.

Opportunities

The pharmaceutical industry is experiencing significant growth worldwide, driven by an aging population, increasing healthcare expenditure, and advancements in medical technology. Torrent Pharmaceuticals Ltd can capitalize on this opportunity by introducing new products and expanding its market share.

The demand for generic drugs is rising globally due to their lower cost compared to branded drugs. Torrent Pharmaceuticals Ltd can leverage this trend by expanding its generic drug portfolio and capturing a larger market share. This can lead to improved profitability and revenue growth.

Threats

The pharmaceutical industry is highly competitive, with numerous players vying for market share. Torrent Pharmaceuticals Ltd faces the risk of intense competition from both domestic and international pharmaceutical companies. Continuous innovation, product differentiation, and strong marketing strategies are essential to mitigate this threat.

The pharmaceutical industry is subject to strict regulations and compliance requirements. Any non-compliance can result in penalties and reputational damage. Torrent Pharmaceuticals Ltd needs to ensure strict adherence to regulatory standards and invest in robust compliance mechanisms to avoid any legal or regulatory issues.

Torrent Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Torrent Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Torrent Pharmaceuticals shares outstanding

The number of shares was Torrent Pharmaceuticals in 2023 — This indicates how many shares 338.445 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Torrent Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Torrent Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Torrent Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Torrent Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Torrent Pharmaceuticals Stock splits

In Torrent Pharmaceuticals's history, there have been no stock splits.

Torrent Pharmaceuticals dividend history and estimates

In 2023, Torrent Pharmaceuticals paid a dividend amounting to 22 INR. Dividend means that Torrent Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Torrent Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Torrent Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Torrent Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Torrent Pharmaceuticals Dividend History

DateTorrent Pharmaceuticals Dividend
2027e29.59 undefined
2026e29.66 undefined
2025e29.5 undefined
202428 undefined
202322 undefined
202216.5 undefined
202117.5 undefined
20208.5 undefined
20198.5 undefined
20187 undefined
20177 undefined
201617.5 undefined
20155.63 undefined
20145 undefined
20133.25 undefined
20122.13 undefined
20111.5 undefined
20101.5 undefined
20091 undefined
20080.88 undefined
20070.75 undefined
20060.63 undefined
20050.5 undefined

Torrent Pharmaceuticals dividend payout ratio

In 2023, Torrent Pharmaceuticals had a payout ratio of 49.02%. The payout ratio indicates the percentage of the company's profits that Torrent Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Torrent Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Torrent Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Torrent Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Torrent Pharmaceuticals Payout Ratio History

DateTorrent Pharmaceuticals Payout ratio
2027e56.54 %
2026e54.66 %
2025e58.94 %
202456.02 %
202349.02 %
202271.77 %
202147.26 %
202028.04 %
201965.94 %
201834.9 %
201725.34 %
201634.13 %
201525.33 %
201425.46 %
201325.41 %
201225.33 %
201118.8 %
201021.96 %
200918.35 %
200821.98 %
200727.17 %
200641.67 %
200534.72 %
Unfortunately, there are currently no price targets and forecasts available for Torrent Pharmaceuticals.

Torrent Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202414.09 13.51  (-4.13 %)2025 Q1
3/31/202413.06 13.27  (1.61 %)2024 Q4
12/31/202312.74 10.5  (-17.58 %)2024 Q3
9/30/202311.08 11.39  (2.75 %)2024 Q2
6/30/202311.08 11.18  (0.88 %)2024 Q1
3/31/20239.83 8.48  (-13.7 %)2023 Q4
12/31/202211.18 8.36  (-25.19 %)2023 Q3
9/30/202214.61 9.22  (-36.89 %)2023 Q2
6/30/202213.76 20.9  (51.91 %)2023 Q1
3/31/20227.74 -2.12  (-127.38 %)2022 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the Torrent Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

83/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

51

Environment

Scope 1 - Direct Emissions
25,063
Scope 2 - Indirect emissions from purchased energy
97,111
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
122,174
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees12
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Torrent Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
71.24568 % Torrent Group241,127,440012/31/2023
1.20766 % Kotak Mahindra Asset Management Company Limited4,087,26042,39012/31/2023
1.01486 % BlackRock Institutional Trust Company, N.A.3,434,74877,4093/31/2024
0.93456 % The Vanguard Group, Inc.3,162,958-2,1883/31/2024
0.77795 % Norges Bank Investment Management (NBIM)2,632,934-45,37312/31/2023
0.73621 % UTI Asset Management Co. Ltd.2,491,665-96,9223/31/2024
0.48517 % Templeton Asset Management Ltd.1,642,04478,42012/31/2023
0.45173 % Candriam Luxembourg S.A.1,528,868-37,9902/29/2024
0.45094 % Nippon Life India Asset Management Limited1,526,18256,7033/31/2024
0.44803 % Fidelity Management & Research Company LLC1,516,32522/29/2024
1
2
3
4
5
...
10

Torrent Pharmaceuticals Executives and Management Board

Shri. Samir Mehta60
Torrent Pharmaceuticals Executive Chairman of the Board (since 2001)
Compensation 230.04 M
Shri. Jinesh Shah46
Torrent Pharmaceuticals Whole-Time Director, Director - Operations (since 2019)
Compensation 58.87 M
Shri. Sudhir Mehta69
Torrent Pharmaceuticals Chairman Emeritus (since 2003)
Compensation 50 M
Mr. Aman Mehta31
Torrent Pharmaceuticals Executive Director (since 2022)
Compensation 20.59 M
Shri. Sudhir Menon
Torrent Pharmaceuticals Chief Financial Officer, Executive Director - Finance
Compensation 16.3 M
1
2
3

Most common questions regarding Torrent Pharmaceuticals

What values and corporate philosophy does Torrent Pharmaceuticals represent?

Torrent Pharmaceuticals Ltd represents values of excellence, integrity, and commitment in the pharmaceutical industry. As one of the largest pharmaceutical companies in India, Torrent Pharmaceuticals is dedicated to providing high-quality and affordable healthcare solutions to patients worldwide. The company's corporate philosophy revolves around innovation, ethical practices, and customer-centricity, ensuring the delivery of safe and effective medicines. With a strong emphasis on research and development, Torrent Pharmaceuticals strives to contribute to the well-being of society by constantly expanding its product portfolio and enhancing healthcare access.

In which countries and regions is Torrent Pharmaceuticals primarily present?

Torrent Pharmaceuticals Ltd is primarily present in multiple countries and regions. The company has a strong global presence and operates in several key markets such as India, the United States, Brazil, Germany, Spain, Russia, and many more. With its diverse geographic footprint, Torrent Pharmaceuticals Ltd has established a wide customer base and significant market reach. The company's global expansion helps facilitate access to its products and allows it to cater to the healthcare needs of various populations around the world.

What significant milestones has the company Torrent Pharmaceuticals achieved?

Torrent Pharmaceuticals Ltd has achieved several significant milestones in its journey. The company has successfully expanded its global presence, entering new markets and launching various products. It has received multiple regulatory approvals for its quality-driven manufacturing facilities, ensuring compliance with international standards. Torrent Pharmaceuticals Ltd has been recognized for its commitment to research and development, developing innovative healthcare solutions and improving patient outcomes. The company has also demonstrated strong financial performance, consistently delivering sustainable growth and creating value for its stakeholders. With its dedication to excellence and continuous improvement, Torrent Pharmaceuticals Ltd continues to make remarkable strides in the pharmaceutical industry.

What is the history and background of the company Torrent Pharmaceuticals?

Torrent Pharmaceuticals Ltd is a reputed pharmaceutical company with a rich history and background. Established in 1959, Torrent Pharmaceuticals has emerged as one of India's leading pharmaceutical companies. With a diverse product portfolio spanning therapeutic areas like cardiovascular, central nervous system, and gastroenterology, the company has made significant contributions to healthcare. Torrent Pharmaceuticals is committed to quality, innovation, and patient-centricity, driving its growth within India and globally. Over the years, the company has garnered recognition for its research and development capabilities, extensive manufacturing infrastructure, and strong ethical practices, making it a trusted player in the pharmaceutical industry.

Who are the main competitors of Torrent Pharmaceuticals in the market?

Torrent Pharmaceuticals Ltd has several main competitors in the market. Some of the prominent competitors of Torrent Pharmaceuticals Ltd include Sun Pharmaceutical Industries Ltd, Lupin Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd, and Aurobindo Pharma Ltd. These companies operate in the same industry and offer similar products and services, leading to competition in the market. However, with its strong market presence and diverse product portfolio, Torrent Pharmaceuticals Ltd continues to strive and maintain its position among the top competitors.

In which industries is Torrent Pharmaceuticals primarily active?

Torrent Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

What is the business model of Torrent Pharmaceuticals?

The business model of Torrent Pharmaceuticals Ltd involves the research, development, production, and marketing of high-quality generic pharmaceuticals and active pharmaceutical ingredients (APIs). As one of the leading players in the Indian pharmaceutical industry, Torrent Pharmaceuticals focuses on delivering affordable and accessible healthcare solutions to a wide range of patients. Their business strategy entails a strong emphasis on product quality, regulatory compliance, and timely introduction of new products. Torrent Pharmaceuticals aims to address various therapeutic segments, including cardiology, diabetology, gastroenterology, and pain management, through a robust portfolio of formulations. The company strives to enhance its global footprint and maintain a strong market position through continuous innovation and strategic partnerships.

What is the P/E ratio of Torrent Pharmaceuticals 2024?

The Torrent Pharmaceuticals P/E ratio is 70.65.

What is the P/S ratio of Torrent Pharmaceuticals 2024?

The Torrent Pharmaceuticals P/S ratio is 10.91.

What is the AlleAktien quality score of Torrent Pharmaceuticals?

The AlleAktien quality score for Torrent Pharmaceuticals is 9/10.

What is the revenue of Torrent Pharmaceuticals 2024?

The Torrent Pharmaceuticals revenue is 107.28 B INR.

How high is the profit of Torrent Pharmaceuticals 2024?

The Torrent Pharmaceuticals profit is 16.56 B INR.

What is the business model of Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd is an Indian pharmaceutical company founded in 1959. It focuses on the manufacturing and distribution of pharmaceuticals and operates in various areas including generics, over-the-counter products, active pharmaceutical ingredients, and bio-pharmacology. The company is known for its cost-effective alternatives to branded drugs and has a strong presence in the Indian and global markets. It specializes in generics, over-the-counter products, active pharmaceutical ingredients, and bio-pharmacology. It has a wide range of products in its portfolio, including anti-infectives, cardiovascular drugs, CNS drugs, gastrointestinal drugs, painkillers, and OTC products. Torrent Pharmaceuticals has a reputation as a leading generic manufacturer in India.

What is the Torrent Pharmaceuticals dividend?

Torrent Pharmaceuticals pays a dividend of 16.5 INR distributed over payouts per year.

How often does Torrent Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Torrent Pharmaceuticals or the company does not pay out a dividend.

What is the Torrent Pharmaceuticals ISIN?

The ISIN of Torrent Pharmaceuticals is INE685A01028.

What is the Torrent Pharmaceuticals ticker?

The ticker of Torrent Pharmaceuticals is TORNTPHARM.NS.

How much dividend does Torrent Pharmaceuticals pay?

Over the past 12 months, Torrent Pharmaceuticals paid a dividend of 28 INR . This corresponds to a dividend yield of about 0.81 %. For the coming 12 months, Torrent Pharmaceuticals is expected to pay a dividend of 29.5 INR.

What is the dividend yield of Torrent Pharmaceuticals?

The current dividend yield of Torrent Pharmaceuticals is 0.81 %.

When does Torrent Pharmaceuticals pay dividends?

Torrent Pharmaceuticals pays a quarterly dividend. This is distributed in the months of March, July, March, July.

How secure is the dividend of Torrent Pharmaceuticals?

Torrent Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of Torrent Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 29.5 INR are expected. This corresponds to a dividend yield of 0.85 %.

In which sector is Torrent Pharmaceuticals located?

Torrent Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Torrent Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Torrent Pharmaceuticals from 7/31/2024 amounting to 6 INR, you needed to have the stock in your portfolio before the ex-date on 6/21/2024.

When did Torrent Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Torrent Pharmaceuticals in the year 2023?

In the year 2023, Torrent Pharmaceuticals distributed 22 INR as dividends.

In which currency does Torrent Pharmaceuticals pay out the dividend?

The dividends of Torrent Pharmaceuticals are distributed in INR.

All fundamentals about Torrent Pharmaceuticals

Our stock analysis for Torrent Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torrent Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.